Who makes MENATETRANONE?

MENATETRANONE is developed by Eisai Limited.

What development phase is MENATETRANONE in?

MENATETRANONE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

MENATETRANONE

Eisai Limited · FDA-approved active Small molecule Quality 6/100

At a glance

Generic name	MENATETRANONE
Sponsor	Eisai Limited
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Vitamin K and Bone Turnover in Postmenopausal Women (PHASE3)
Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women (PHASE3)
Randomized, Open, Parallel, Active Controlled Study on Fracture Prevention in Antiosteoporosis Treatment (OF Study) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MENATETRANONE CI brief — competitive landscape report
MENATETRANONE updates RSS · CI watch RSS
Eisai Limited portfolio CI